Completed PHASE2 INTERVENTIONAL 1-arm NCT00532259

CT-011 MAb in DLBCL Patients Following ASCT

Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation

Sponsor: CureTech Ltd

Conditions Lymphoma, Large Cell, Diffuse Lymphoma, Mixed Cell, Diffuse Primary Mediastinal Large B-Cell Lymphoma

Interventions CT-011

Updated 7 times since 2017 Last updated: Sep 8, 2014 Started: Oct 31, 2007 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00532259, this PHASE2 trial focuses on Lymphoma, Large Cell, Diffuse and Lymphoma, Mixed Cell, Diffuse and remains completed. Sponsored by CureTech Ltd, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CureTech Ltd

Data source: CureTech Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Ann Arbor, United States , Atlanta, United States , Boston, United States , Chapel Hill, United States , Chicago, United States , Cleveland, United States , Colombus, United States , Dallas, United States , Delhi, India and 14 more locations